| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-686
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-4283
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-536
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-303
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-248
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-4291 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 |
| filingDate |
2020-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af226973a2cded1df8049b2cdb9fa5d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a537d8c812a62ee64ebc53fa69b55716 |
| publicationDate |
2020-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2020055872-A |
| titleOfInvention |
Pharmaceuticals containing a carrier into cells that form an immune complex |
| abstract |
An object of the present invention is to provide a method for using an antigen-binding molecule to eliminate an antigen from plasma. The present invention uses an antigen-binding molecule comprising an Fc region and two or more antigen-binding domains, wherein at least one of the domains is an antigen-binding domain whose antigen-binding activity changes depending on ion concentration conditions. The antigen from the plasma of an antigen-binding molecule capable of forming an immune complex containing an antigen-binding molecule of at least one molecule and (b) two or more antigens (however, the antigen includes two or more antigen-binding units). How to use to make it disappear. The method of use, wherein the condition of the ion concentration is a Ca ion concentration, and the binding domain is an antigen domain whose binding activity to an antigen at a low Ca ion concentration is lower than that at a high Ca ion concentration. Further, the use method wherein the ion concentration condition is a pH condition, and the antigen-binding activity of the antigen in a pH acidic range is lower than the antigen-binding activity in a neutral pH range. [Selection diagram] None |
| priorityDate |
2011-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |